August 10, 2026

Hims Q2 $753M +38% + FY Guidance Raised, CagriSema REDEFINE 4 vs Zepbound Detail, Wegovy 7.2 mg FDA Review

Hims Q2 $753M +38% and FY guidance raised to $3.1-3.3B despite 76%→64% gross margin drop. CagriSema REDEFINE 4 84-week detail. Wegovy 7.2 mg FDA review.

4 stories · Covering industry, clinical-trials, regulatory

Editor's Note

Monday's peptide news anchors on Hims & Hers Health's (NYSE: HIMS) Q2 2026 earnings print after market close, with revenue of $753.2 million (+38% year-over-year) crushing consensus and full-year 2026 guidance raised to $3.1-3.3 billion in revenue and $275-325 million in Adjusted EBITDA. US revenue reached $621.8 million (+16%); international revenue climbed to $131.4 million (+17-fold YoY through the Eucalyptus acquisition that closed June). Subscribers reached approximately 2.9 million (+19% YoY). The catch: gross margin compressed to 64% from 76% year-ago on the pivot from compounded to branded GLP-1s (Wegovy/Ozempic/Zepbound/Mounjaro through Novo and Lilly commercial partnerships), and the company reported a net loss of $86.3 million versus $42.5 million net income in Q2 2025. The FTC lawsuit filed July 29 alleging consumer health-data sharing with Meta and Snap plus unauthorized billing remains a substantive overhang. Novo Nordisk's REDEFINE 4 head-to-head 84-week Phase 3 trial detail on CagriSema (cagrilintide 2.4 mg + semaglutide 2.4 mg fixed-dose combination) versus tirzepatide 15 mg in 809 adults with obesity documented 23.0% vs 25.5% weight loss (treatment-policy estimand) and 20.2% vs 23.6% (treatment-regimen estimand), missing the primary non-inferiority endpoint. CagriSema safety profile was described as generally well-tolerated. The higher-dose Wegovy 7.2 mg (semaglutide 7.2 mg once weekly, up from the current 2.4 mg maximum) is currently under FDA review with clinical-trial data supporting approximately 19% weight loss (versus approximately 15% for the 2.4 mg dose).

Industry

Hims & Hers Health (NYSE: HIMS) Q2 2026 Earnings Print After Market Close Monday August 10 With Revenue of $753.2 Million (+38% Year-Over-Year, Beating Consensus of $698.9 Million); US Revenue $621.8 Million (+16%), International Revenue $131.4 Million (+17-Fold YoY Aided by Eucalyptus Acquisition Completed June); Subscribers Reached Approximately 2.9 Million (+19% YoY); Full-Year 2026 Guidance Raised to $3.1-3.3 Billion in Revenue and $275-325 Million in Adjusted EBITDA; Net Loss of $86.3 Million Versus $42.5 Million Net Income in Q2 2025 With Gross Margin Compressed to 64% From 76% Year-Ago on the Compounded-to-Branded GLP-1 Pivot; FTC Lawsuit Filed July 29 Alleging Consumer Health-Data Sharing With Meta and Snap Remains Substantive Overhang

Hims & Hers Health (NYSE: HIMS) reported Q2 2026 earnings after market close Monday August 10, 2026. Revenue reached $753.2 million (+38% year-over-year), beating consensus of $698.9 million. US revenue was $621.8 million (+16% YoY); international revenue climbed to $131.4 million (+17-fold year-over-year) aided by the completion of the Eucalyptus acquisition in June 2026. Subscribers grew to approximately 2.9 million (+19% YoY). The company raised full-year 2026 guidance to $3.1-3.3 billion in revenue and $275-325 million in Adjusted EBITDA. Net loss was $86.3 million versus $42.5 million net income in Q2 2025 as gross margin compressed to 64% from 76% year-ago; the compression reflects the strategic pivot from compounded GLP-1s (higher margin) to branded GLP-1 supply (lower margin) through Novo Nordisk (Wegovy, Ozempic) and Eli Lilly (Zepbound, Mounjaro) commercial partnerships since Q1 2026. The FTC lawsuit filed July 29 alleging the company shared consumer sensitive health information with Meta Platforms and Snap Inc. through embedded tracking technologies and separately alleging unauthorized billing charges (with Los Angeles County and Utah as co-plaintiffs) remains a substantive overhang. Chief Medical Officer Dr. Anant Vinjamoori's July 23 PCAC harm-reduction testimony framing continues to shape the post-PCAC peptide-strategy narrative.

#hims-hers #hims #q2-2026-earnings #753-million-revenue #eucalyptus-acquisition #compounded-to-branded #gross-margin-compression #ftc-lawsuit #guidance-raised #2-9-million-subscribers

Clinical Trials

Novo Nordisk REDEFINE 4 Head-to-Head 84-Week Phase 3 Trial Detail: CagriSema (Cagrilintide 2.4 mg + Semaglutide 2.4 mg Fixed-Dose Combination) Versus Tirzepatide 15 mg in 809 Randomized Adults With Obesity and One or More Comorbidities With Mean Baseline Body Weight of 114.2 kg Documented 23.0% Weight Loss on CagriSema Versus 25.5% on Tirzepatide (Treatment-Policy Estimand) and 20.2% Versus 23.6% (Treatment-Regimen Estimand), Missing the Primary Non-Inferiority Endpoint; CagriSema Safety Profile Was Generally Well-Tolerated; The Trial Result Complicates the Novo Commercial Positioning of CagriSema as Its Tirzepatide-Beating Response Even as the FDA Decision on the Obesity Indication (Filed December 18, 2025 Based on REDEFINE 1 and REDEFINE 2 Pivotal Data) Remains Expected Late 2026

Novo Nordisk released detailed data from the REDEFINE 4 head-to-head 84-week Phase 3 trial of CagriSema (cagrilintide 2.4 mg + semaglutide 2.4 mg fixed-dose combination) versus tirzepatide 15 mg. Trial design: 809 randomized adults with obesity and one or more comorbidities with mean baseline body weight of 114.2 kg, both drugs administered once weekly subcutaneously over 84 weeks. Primary endpoint results: CagriSema 23.0% weight loss versus tirzepatide 25.5% (treatment-policy estimand); CagriSema 20.2% versus tirzepatide 23.6% (treatment-regimen estimand). The trial missed the primary non-inferiority endpoint on weight loss for CagriSema compared to tirzepatide at 84 weeks. CagriSema safety profile was generally well-tolerated. The trial result complicates the Novo commercial positioning of CagriSema as its tirzepatide-beating differentiated response, though the FDA decision on the CagriSema obesity indication remains expected late 2026 based on the REDEFINE 1 and REDEFINE 2 pivotal trials submitted December 18, 2025. The head-to-head result adds to the widening Lilly-Novo franchise gap: Lilly Q2 2026 Mounjaro + Zepbound reached $14.9 billion in the quarter, while Novo H1 2026 sales reached 78.49 billion Danish kroner ($12.09 billion).

#novo-nordisk #cagrisema #cagrilintide #semaglutide #tirzepatide #redefine-4 #phase-3 #head-to-head #obesity #non-inferiority-miss #84-week

Regulatory

Higher-Dose Wegovy 7.2 mg (Semaglutide 7.2 mg Once Weekly Subcutaneous Injection, Up From the Current 2.4 mg Maximum Approved Dose) Is Under FDA Review for the Adult Obesity Indication Based on Phase 3 STEP UP Trial Data That Documented Approximately 19% Weight Loss at the 7.2 mg Dose Versus Approximately 15% for the Current 2.4 mg Dose, Providing Novo Nordisk With a Higher-Efficacy Line-Extension Option Even as the Lilly Tirzepatide Franchise (Zepbound, Mounjaro) Continues to Outperform on Weight Loss (Approximately 21% for 15 mg Weekly) and Lilly's Retatrutide Triple-Agonist Phase 3 Data Has Documented 28.7% Weight Loss at the 12 mg Dose in TRIUMPH-4

The higher-dose Wegovy 7.2 mg (semaglutide 7.2 mg once weekly subcutaneous injection, up from the current 2.4 mg maximum approved dose) is currently under FDA review for the adult obesity indication. The submission is based on the Phase 3 STEP UP trial that documented approximately 19% weight loss at the 7.2 mg dose over 68 weeks, versus approximately 15% weight loss for the currently-approved 2.4 mg dose (based on STEP 1 registrational data). The higher-dose submission provides Novo Nordisk with a line-extension option to defend the Wegovy franchise economics against the Eli Lilly tirzepatide franchise (Zepbound and Mounjaro), which continues to outperform on weight loss (approximately 21% at the 15 mg weekly dose per SURMOUNT-1). The Wegovy 7.2 mg efficacy also lags the Lilly retatrutide triple-agonist Phase 3 TRIUMPH-4 data that documented 28.7% mean body weight reduction at the 12 mg dose (the highest weight-loss magnitude in any Phase 3 obesity trial to date). Novo Nordisk's line-extension strategy is under scrutiny following the CagriSema REDEFINE 4 head-to-head miss versus tirzepatide (23.0% vs 25.5% treatment-policy estimand at 84 weeks). FDA decision timing on Wegovy 7.2 mg has not been publicly disclosed.

#novo-nordisk #wegovy #wegovy-7-2-mg #higher-dose #semaglutide #step-up #fda-review #line-extension #tirzepatide #retatrutide #triumph-4

Industry

Post-PCAC Telehealth Peptide Competitive Landscape Synthesis: Hims & Hers Health (NYSE: HIMS) Q2 $753M Revenue Reported Monday After Market Close, LifeMD (NASDAQ: LFMD) Approximately 310,000 Active Telehealth Subscribers Per Recent Investor Materials, Ro and Henry Meds Rounding Out the Large-Player Set; Alliance for Pharmacy Compounding, Empower Pharmacy, and American Institute for Compounded Therapeutics Were Among Key Institutional Commenters Supporting the July 23-24, 2026 PCAC 6-of-7 Vote Recommendation That Set Up the Prospective Legal-Compounding Channel for BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon Once FDA Rulemaking Completes (Typically 12-24 Months)

The post-PCAC telehealth peptide competitive landscape continues to shape investor attention. Hims & Hers Health (NYSE: HIMS) Q2 2026 revenue of $753.2 million (+38% YoY) reported Monday August 10 after market close positions Hims as the largest US telehealth peptide-strategy sponsor. LifeMD (NASDAQ: LFMD) has approximately 310,000 active telehealth subscribers per recent investor materials, with 2025 revenue guided at $265-275 million. Ro and Henry Meds round out the large-player telehealth set. Key institutional commenters supporting the July 23-24, 2026 FDA Pharmacy Compounding Advisory Committee (PCAC) 6-of-7 vote recommendation included the Alliance for Pharmacy Compounding, Empower Pharmacy, American Institute for Compounded Therapeutics, Texas Pharmacy Association, real-world data platform Peptide AI, and the American Academy of Peptide Medicine. The July 23-24 vote recommendation (BPC-157, KPV, TB-500, MOTS-c, Semax, Epitalon approved 6 of 7; Emideltide/DSIP rejected) sets up the prospective legal compounding channel once FDA rulemaking completes (typically 12-24 months per PCAC-recommended substance). Enforcement context: the FDA issued 40+ warning letters and 100+ cease-and-desist notices to compounders and telehealth companies in 2024-2025 (the single largest enforcement action in compounding-pharmacy regulation history), and by March 2026 the FDA had sent warning letters to 30 additional telehealth companies with total enforcement actions exceeding 125 warning and untitled letters. The February 2027 PCAC second-peptide meeting (LL-37, GHK-Cu, dihexa acetate, melanotan II, PEG-MGF) will further shape the compounding landscape.

#hims-hers #lifemd #lfmd #ro #henry-meds #telehealth-peptide-landscape #alliance-for-pharmacy-compounding #empower-pharmacy #peptide-compounding #fda-enforcement #post-pcac